Skip to main content
Evidence Snapshot

Polyunsaturated fatty acid lipoxygenase ALOX15

CHEMBL4358 SINGLE PROTEIN Oryctolagus cuniculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4358
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Polyunsaturated fatty acid lipoxygenase ALOX15 as ChEMBL target CHEMBL4358, mapped to UniProt P12530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Polyunsaturated fatty acid lipoxygenase ALOX15
SINGLE PROTEIN · Oryctolagus cuniculus
As of 2026-09-14
ChEMBL target ID
CHEMBL4358
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P12530
Polyunsaturated fatty acid lipoxygenase ALOX15
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Polyunsaturated fatty acid lipoxygenase ALOX15 matters

As of 2026-09-14

Polyunsaturated fatty acid lipoxygenase ALOX15 is reviewed as Polyunsaturated fatty acid lipoxygenase ALOX15 (UniProt P12530); the current evidence base includes 32 approved drugs, 1017 compounds, and 35 assays, with lead potency reaching pChEMBL 8.8.

Protein context
Polyunsaturated fatty acid lipoxygenase ALOX15

Polyunsaturated fatty acid lipoxygenase ALOX15 Sequence length is 663 aa.

Review this target as Polyunsaturated fatty acid lipoxygenase ALOX15, mapped to UniProt P12530. Sequence length is 663 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P12530 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 1017 compounds, and 35 assays for this target. The dominant activity type is IC50. CHEMBL1796851 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL1796851 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
32 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Polyunsaturated fatty acid lipoxygenase ALOX15 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P12530, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1017
Total Compounds
35
Total Assays
32
Approved Drugs
IC50: 1117.0, KI: 840.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1796851
8.8 IC50
No preferred name
CHEMBL1796845
8.8 IC50
No preferred name
CHEMBL1796849
8.7 IC50
No preferred name
CHEMBL1796846
8.7 IC50
No preferred name
CHEMBL1796850
8.6 IC50

Approved Drugs

Structure Compound First Approval
MIFEPRISTONE
CHEMBL1276308
2000
TANNIC ACID
CHEMBL506247
1982
DOBUTAMINE
CHEMBL926
1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4358